» Articles » PMID: 24084736

Divergence of IL-1, IL-18, and Cell Death in NLRP3 Inflammasomopathies

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2013 Oct 3
PMID 24084736
Citations 112
Authors
Affiliations
Soon will be listed here.
Abstract

The inflammasome is a cytoplasmic multiprotein complex that promotes proinflammatory cytokine maturation in response to host- and pathogen-derived signals. Missense mutations in cryopyrin (NLRP3) result in a hyperactive inflammasome that drives overproduction of the proinflammatory cytokines IL-1β and IL-18, leading to the cryopyrin-associated periodic syndromes (CAPS) disease spectrum. Mouse lines harboring CAPS-associated mutations in Nlrp3 have elevated levels of IL-1β and IL-18 and closely mimic human disease. To examine the role of inflammasome-driven IL-18 in murine CAPS, we bred Nlrp3 mutations onto an Il18r-null background. Deletion of Il18r resulted in partial phenotypic rescue that abolished skin and visceral disease in young mice and normalized serum cytokines to a greater extent than breeding to Il1r-null mice. Significant systemic inflammation developed in aging Nlrp3 mutant Il18r-null mice, indicating that IL-1 and IL-18 drive pathology at different stages of the disease process. Ongoing inflammation in double-cytokine knockout CAPS mice implicated a role for caspase-1-mediated pyroptosis and confirmed that CAPS is inflammasome dependent. Our results have important implications for patients with CAPS and residual disease, emphasizing the need to explore other NLRP3-mediated pathways and the potential for inflammasome-targeted therapy.

Citing Articles

GSDMD-mediated pyroptosis: molecular mechanisms, diseases and therapeutic targets.

Li Y, Guo B Mol Biomed. 2025; 6(1):11.

PMID: 39994107 PMC: 11850691. DOI: 10.1186/s43556-025-00249-8.


Pyroptotic cell corpses are crowned with F-actin-rich filopodia that engage CLEC9A signaling in incoming dendritic cells.

Holley C, Monteleone M, Fisch D, Libert A, Ju R, Choi J Nat Immunol. 2024; 26(1):42-52.

PMID: 39633178 PMC: 11695261. DOI: 10.1038/s41590-024-02024-3.


Inflammasome components as new therapeutic targets in inflammatory disease.

Coll R, Schroder K Nat Rev Immunol. 2024; 25(1):22-41.

PMID: 39251813 DOI: 10.1038/s41577-024-01075-9.


Unraveling the role of NLRP3 inflammasome in allergic inflammation: implications for novel therapies.

Lu H, Zhou Y, Hu T, Yang D, Wang X, Luo D Front Immunol. 2024; 15:1435892.

PMID: 39131161 PMC: 11310156. DOI: 10.3389/fimmu.2024.1435892.


The interplay of transition metals in ferroptosis and pyroptosis.

Vana F, Szabo Z, Masarik M, Kratochvilova M Cell Div. 2024; 19(1):24.

PMID: 39097717 PMC: 11297737. DOI: 10.1186/s13008-024-00127-9.


References
1.
Meinzer U, Quartier P, Alexandra J, Hentgen V, Retornaz F, Kone-Paut I . Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011; 41(2):265-71. DOI: 10.1016/j.semarthrit.2010.11.003. View

2.
Novick D, Kim S, Fantuzzi G, Reznikov L, Dinarello C, Rubinstein M . Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity. 1999; 10(1):127-36. DOI: 10.1016/s1074-7613(00)80013-8. View

3.
Schmidt R, Lenz L . Distinct licensing of IL-18 and IL-1β secretion in response to NLRP3 inflammasome activation. PLoS One. 2012; 7(9):e45186. PMC: 3445464. DOI: 10.1371/journal.pone.0045186. View

4.
Pomerantz B, Reznikov L, Harken A, Dinarello C . Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A. 2001; 98(5):2871-6. PMC: 30232. DOI: 10.1073/pnas.041611398. View

5.
Dinarello C, Fantuzzi G . Interleukin-18 and host defense against infection. J Infect Dis. 2003; 187 Suppl 2:S370-84. DOI: 10.1086/374751. View